A salt represented by formula (I): ##STR00001##
wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxy group or a C.sub.1 to C.sub.12 hydrocarbon group in which a methylene group may be replaced by a —O— or —CO—; m and n independently represent 1 or 2; Ar represents an optionally substituted phenyl group; Q.sup.1 and Q.sup.2 independently represent a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, A.sup.1 represents a single bond, a C.sub.1 to C.sub.24 alkanediyl group or the like, and Y represents an optionally substituted C.sub.1 to C.sub.18 alkyl group or monovalent C.sub.3 to C.sub.18 alicyclic hydrocarbon group, and a methylene group therein may be replaced by a —O—, O— or —SO.sub.2—, provided that the alkyl group or the alicyclic hydrocarbon group has at least one substituent, or at least one methylene group contained therein is replaced by a —O—, —CO— or —SO.sub.2—.

A salt represented by formula (I): ##STR00001##
wherein R.sup.1 and R.sup.2 independently represent a hydrogen atom, a hydroxy group or a C.sub.1 to C.sub.12 hydrocarbon group in which a methylene group may be replaced by a —O— or —CO—; m and n independently represent 1 or 2; Ar represents an optionally substituted phenyl group; Q.sup.1 and Q.sup.2 independently represent a fluorine atom or a C.sub.1 to C.sub.6 perfluoroalkyl group, A.sup.1 represents a single bond, a C.sub.1 to C.sub.24 alkanediyl group or the like, and Y represents an optionally substituted C.sub.1 to C.sub.18 alkyl group or monovalent C.sub.3 to C.sub.18 alicyclic hydrocarbon group, and a methylene group therein may be replaced by a —O—, O— or —SO.sub.2—, provided that the alkyl group or the alicyclic hydrocarbon group has at least one substituent, or at least one methylene group contained therein is replaced by a —O—, —CO— or —SO.sub.2—.

Process for the preparation of a compound with at least one five-membered cyclic monothiocarbonate group wherein a) a compound with at least one epoxy group is used as starting material b) the compound is reacted with phosgene or an alkyl chloroformate thus giving an adduct and c) the adduct is reacted with a compound comprising anionic sulfurthus obtaining the compound with at least one five-membered cyclic monothiocarbonate group.

Process for the preparation of a compound with at least one five-membered cyclic monothiocarbonate group wherein a) a compound with at least one epoxy group is used as starting material b) the compound is reacted with phosgene or an alkyl chloroformate thus giving an adduct and c) the adduct is reacted with a compound comprising anionic sulfurthus obtaining the compound with at least one five-membered cyclic monothiocarbonate group.

Provided is an organic electrolyte solution that includes a lithium salt, an organic solvent, and a sulfonate ester-based compound represented by Formula 1:

R.sub.2—O—S(═O).sub.2—R.sub.1  <Formula 1> wherein, in Formula 1, R.sub.1 may be a C1-C20 alkyl group that is unsubstituted or substituted with halogen, a C5-C20 cycloalkyl group that is unsubstituted or substituted with halogen, a C6-C40 aryl group that is unsubstituted or substituted with halogen, or a C2-C40 heteroaryl group that is unsubstituted or substituted with halogen, and R.sub.2 may be a substituted or unsubstituted cyclic sulfone group.

A process prepares a prepolymer containing a urethane group and a curable silicon-functional group, or a prepolymer of formula (IV),

##STR00001##

The prepolymer may be cured to a cross-linked polymer by ambient moisture and is therefore suitable for use as a component in a one-component sealant or adhesive composition.

Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.

The present invention relates to 1,3-oxathiolane-2-thione derivatives, to a method for the production thereof, and to the uses thereof. The present invention also relates to silylated polymers obtained from said 1,3-oxathiolane-2-thione derivatives, and also to formulations comprising them.

The present invention relates to 1,3-oxathiolane-2-thione derivatives, to a method for the production thereof, and to the uses thereof. The present invention also relates to silylated polymers obtained from said 1,3-oxathiolane-2-thione derivatives, and also to formulations comprising them.